*Stocks in News*☘️☘️☘️
*Adani Enterprises:* Sebi held Adani Wilmar IPO due to investigation against Adani Enterprises.
*Arvind Fashions:* The company raised Rs 439 crore from marquee investors including promoters at a price of Rs 218.50 per equity share.
*Aurobindo Pharma:* The company approved the termination of binding agreements with Cronus Pharma Specialities India for acquisition of 51% ownership in Cronus Pharma, for Rs 420 crore.
*Cadila Healthcare:* Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19.
*Adani Total Gas:* The company to acquire 50% stake in Smartmeters Technologies.
*TTK Prestige:* Long-term settlement has been reached with the permanent workmen at manufacturing unit at Khardi, Maharashtra.
*Adani Enterprises:* Sebi held Adani Wilmar IPO due to investigation against Adani Enterprises.
*Arvind Fashions:* The company raised Rs 439 crore from marquee investors including promoters at a price of Rs 218.50 per equity share.
*Aurobindo Pharma:* The company approved the termination of binding agreements with Cronus Pharma Specialities India for acquisition of 51% ownership in Cronus Pharma, for Rs 420 crore.
*Cadila Healthcare:* Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19.
*Adani Total Gas:* The company to acquire 50% stake in Smartmeters Technologies.
*TTK Prestige:* Long-term settlement has been reached with the permanent workmen at manufacturing unit at Khardi, Maharashtra.
Infosys 🔥🔥🔥
Ministry of Finance has summoned Salil Parekh, MD & CEO Infosys on Aug 23 to explain why even after 2.5 months since launch of new e-filing portal, glitches in the portal have not been resolved.
❌In fact, since Aug 21 the portal itself is not available.
Ministry of Finance has summoned Salil Parekh, MD & CEO Infosys on Aug 23 to explain why even after 2.5 months since launch of new e-filing portal, glitches in the portal have not been resolved.
❌In fact, since Aug 21 the portal itself is not available.
Stocks with High Promoter Pledge as on 30th June
Large Caps
Vedanta 100% Promoter Holding Pledged
IndusInd Bank 45.5%
Indus Towers 40.3%
Hindustan Zinc 22.8%
Aurobindo Pharma 20.7%
JSW Steel 22.8%
Adani Ports 14.4%
Large Caps
Vedanta 100% Promoter Holding Pledged
IndusInd Bank 45.5%
Indus Towers 40.3%
Hindustan Zinc 22.8%
Aurobindo Pharma 20.7%
JSW Steel 22.8%
Adani Ports 14.4%
Pledge Share Details
Wockhardt: Promoter Themisto Trustee Company created a pledge of 30,000 shares on August 17.
Wockhardt: Promoter Themisto Trustee Company created a pledge of 30,000 shares on August 17.
💉 Zydus Cadila Aims To Deliver Up To 5 Crore Doses Of ZyCov-D Covid Vaccine By January 2022
The Ahmedabad-based pharmaceuticals firm will start producing one crore doses per month of the ZyCov-D vaccine from October, Managing Director Sharvil Patel said in a press conference. "We hope to supply three to five crore doses by the end of January 2022."
Highlights from Zydus Cadila's press conference
Will work closely with regulators to work on the pricing and modalities of ZyCoV-D doses.
Will have a clear answer on pricing in the next 1-2 weeks.
Expect to start delivering doses to the government by the start of September.
Large part of the capacity will be delivered to the central government, which will then get distributed to the states.
Will also provide the opportunity to the private market to get access to the vaccine.
ZyCoV-D can be stored at 2-8 degree Celsius and has shown stability at 25 degree Celsius for at least three months.
This will allow for easy transportation and storage and reduce cold chain challenges.
Have invested around Rs 500 crore so far; will have to make further investments.
Largely funded the vaccine development through internal resources.
ZyCov-D vaccine, developed domestically by Zydus Cadila in partnership with the Department of Biotechnology, had shown an efficacy of 66.6%, according to the interim results from phase-3 clinical trials.
The Ahmedabad-based pharmaceuticals firm will start producing one crore doses per month of the ZyCov-D vaccine from October, Managing Director Sharvil Patel said in a press conference. "We hope to supply three to five crore doses by the end of January 2022."
Highlights from Zydus Cadila's press conference
Will work closely with regulators to work on the pricing and modalities of ZyCoV-D doses.
Will have a clear answer on pricing in the next 1-2 weeks.
Expect to start delivering doses to the government by the start of September.
Large part of the capacity will be delivered to the central government, which will then get distributed to the states.
Will also provide the opportunity to the private market to get access to the vaccine.
ZyCoV-D can be stored at 2-8 degree Celsius and has shown stability at 25 degree Celsius for at least three months.
This will allow for easy transportation and storage and reduce cold chain challenges.
Have invested around Rs 500 crore so far; will have to make further investments.
Largely funded the vaccine development through internal resources.
ZyCov-D vaccine, developed domestically by Zydus Cadila in partnership with the Department of Biotechnology, had shown an efficacy of 66.6%, according to the interim results from phase-3 clinical trials.
DOW JONES UP 236
NASDAQ UP 46
DOW FUTURE UP 77
NASDAQ FUTURE UP 38
SGX NIFTY UP 148
NASDAQ UP 46
DOW FUTURE UP 77
NASDAQ FUTURE UP 38
SGX NIFTY UP 148
Market Wizard
Sceeenshot proof of buying at 315.8 also. Guys please don't miss. All quality stocks will rocket 🚀. Hindcompos is high conviction bet
HIND COMPOS 317.7❤️❤️❤️
ADDED AT ALL LOWER LEVELS OF 295 - 298 - 300 - 302
ADDED AT ALL LOWER LEVELS OF 295 - 298 - 300 - 302